Lucas P, Anderson K, Staniforth J N
Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, U.K.
Pharm Res. 1998 Apr;15(4):562-9. doi: 10.1023/a:1011977826711.
To evaluate the use of carrier-based dry powder aerosols for inhalation delivery of proteins and examine the effect of fine particle excipients as potential formulation performance modifiers.
Bovine serum albumin (BSA) was co-processed with maltodextrin by spray-drying to produce model protein particles. Aerosol formulations were prepared by tumble mixing protein powders with alpha-lactose monohydrate (63-90 microns) or modified lactoses containing between 2.5 and 10% w/w fine particle lactose (FPL) or micronised polyethylene glycol 6000. Powder blends were characterised in terms of particle size distribution, morphology and powder flow. Formulation performance in Diskhaler and Rotahaler devices was investigated using a twin stage impinger operating at 60.s51 min-1.
Inhalation performance of binary ordered mixes prepared using BSA-maltodextrin and lactose (63-90 microns) was improved by addition of FPL and micronised PEG 6000. For the addition of 5% w/w FPL the protein fine particle fraction (0.5-6.4 microns) using the Diskhaler was increased from 31.7 +/- 2.4% to 47.4 +/- 2.2%. Inclusion of FPL and micronised PEG 6000 changed the bulk properties of inhalation powders and reduced powder flow but did not affect device emptying. Unexpectedly, improvements in performance were found to be independent of the order of addition of FPL to the ternary powder formulations. SEM studies revealed that this was probably the result of a redistribution of protein particles between the coarse carrier lactose component and added FPL during mixing.
Fine particle excipients can be used to improve the performance of carrier-based protein dry powder aerosols. Mechanistically, enhancement of performance is proposed to result from a redistribution of protein particles from coarse carrier particles to the fine particle component in the ternary mix.
评估基于载体的干粉气雾剂用于蛋白质吸入给药的情况,并研究细颗粒赋形剂作为潜在制剂性能调节剂的作用。
通过喷雾干燥将牛血清白蛋白(BSA)与麦芽糊精共同加工,以制备模型蛋白质颗粒。通过将蛋白质粉末与一水合α-乳糖(63 - 90微米)或含有2.5%至10% w/w细颗粒乳糖(FPL)或微粉化聚乙二醇6000的改性乳糖进行翻滚混合来制备气雾剂制剂。对粉末混合物的粒度分布、形态和粉末流动性进行了表征。使用在60.s51分钟-1运行的两级撞击器研究了Diskhaler和Rotahaler装置中的制剂性能。
使用BSA - 麦芽糊精和乳糖(63 - 90微米)制备的二元有序混合物的吸入性能通过添加FPL和微粉化PEG 6000得到改善。对于添加5% w/w FPL的情况,使用Diskhaler时蛋白质细颗粒部分(0.5 - 6.4微米)从31.7 +/- 2.4%增加到47.4 +/- 2.2%。包含FPL和微粉化PEG 6000改变了吸入粉末的整体性质并降低了粉末流动性,但不影响装置排空。出乎意料的是,发现性能的改善与FPL添加到三元粉末制剂中的顺序无关。扫描电子显微镜研究表明,这可能是由于在混合过程中蛋白质颗粒在粗载体乳糖成分和添加的FPL之间重新分布的结果。
细颗粒赋形剂可用于改善基于载体的蛋白质干粉气雾剂的性能。从机制上讲,性能的提高被认为是由于蛋白质颗粒从粗载体颗粒重新分布到三元混合物中的细颗粒成分所致。